Servier Completes Edgewise Muscular Dystrophy Acquisition | Lucid Diligence Brief
Servier Completes the Edgewise Muscular Dystrophy Acquisition and Adds…
Warburg Pincus PANTHERx Rare Acquisition | Lucid Diligence Brief
Warburg Pincus to acquire control of PANTHERx Rare, backing expansion of the…
United Therapeutics’ Thymmune acquisition | Lucid Diligence Brief
United Therapeutics adds Thymmune’s iPSC thymic-cell platform to its…
SERB–Hansa Idefirix Deal | Lucid Diligence Brief
SERB’s Idefirix rights acquisition from Hansa Biopharma sharpens its rare…
AI in Healthcare and Digital Health Today—June 23, 2026
This week’s AI in Healthcare and Digital Health update highlights…
Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief
Ascidian and Lilly $1.9B collaboration tests whether RNA exon editing can move…
Servier Edgewise Sevasemten Deal | Lucid Diligence Brief
Servier’s Edgewise acquisition puts sevasemten’s Becker muscular dystrophy data…
Secretome STM-01 Duchenne Cardiomyopathy | Lucid Diligence Brief
Secretome’s STM-01 faces Duchenne cardiomyopathy endpoint, CMC, and regulatory…
Lucid Diligence Brief: Genethon and Ampersand Biomedicines AAV Partnership
Lucid Diligence Brief: Genethon and Ampersand Biomedicines partner to design…
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic partnership for late-phase AAV manufacturing
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic…
Lucid Diligence Brief: Blackstone Life Sciences $250 million investment in Anagram Therapeutics
Lucid Diligence Brief: Blackstone Life Sciences $250 million investment in…
Lucid Diligence Brief: Apertura Gene Therapy and TSC Alliance Collaboration
Lucid Diligence Brief: Apertura Gene Therapy and TSC Alliance Collaboration…